Quest Diagnostics (DGX) to Release Quarterly Earnings on Tuesday
by Scott Moore · The Cerbat GemQuest Diagnostics (NYSE:DGX – Get Free Report) is expected to issue its Q1 2026 results before the market opens on Tuesday, April 21st. Analysts expect the company to announce earnings of $2.37 per share and revenue of $2.8266 billion for the quarter. Quest Diagnostics has set its FY 2026 guidance at 9.45-9.650 EPS. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, April 21, 2026 at 8:30 AM ET.
Quest Diagnostics (NYSE:DGX – Get Free Report) last issued its quarterly earnings results on Tuesday, February 10th. The medical research company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.35 by $0.07. The company had revenue of $2.81 billion during the quarter, compared to analysts’ expectations of $2.75 billion. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.57%. The business’s quarterly revenue was up 7.1% on a year-over-year basis. During the same period last year, the business earned $2.23 EPS. On average, analysts expect Quest Diagnostics to post $10 EPS for the current fiscal year and $10 EPS for the next fiscal year.
Quest Diagnostics Stock Performance
Shares of DGX stock opened at $194.88 on Monday. Quest Diagnostics has a 12 month low of $160.02 and a 12 month high of $213.50. The company’s fifty day simple moving average is $200.42 and its 200-day simple moving average is $188.73. The firm has a market cap of $21.57 billion, a PE ratio of 22.27, a P/E/G ratio of 2.52 and a beta of 0.66. The company has a quick ratio of 0.96, a current ratio of 1.04 and a debt-to-equity ratio of 0.72.
Quest Diagnostics announced that its board has initiated a stock repurchase program on Tuesday, February 10th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to buy up to 4.7% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its stock is undervalued.
Quest Diagnostics Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Monday, April 20th. Shareholders of record on Monday, April 6th will be given a dividend of $0.86 per share. This is a boost from Quest Diagnostics’s previous quarterly dividend of $0.80. The ex-dividend date of this dividend is Monday, April 6th. This represents a $3.44 annualized dividend and a yield of 1.8%. Quest Diagnostics’s payout ratio is presently 39.31%.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on DGX shares. Wall Street Zen downgraded Quest Diagnostics from a “buy” rating to a “hold” rating in a report on Sunday, March 15th. Mizuho increased their price target on Quest Diagnostics from $210.00 to $235.00 and gave the company an “outperform” rating in a research note on Thursday, February 12th. Jefferies Financial Group raised their price target on Quest Diagnostics from $215.00 to $220.00 and gave the company a “buy” rating in a report on Tuesday, February 10th. Truist Financial lifted their price objective on shares of Quest Diagnostics from $205.00 to $220.00 and gave the stock a “hold” rating in a research report on Wednesday, February 11th. Finally, Evercore set a $210.00 price objective on shares of Quest Diagnostics in a report on Wednesday, April 8th. Seven equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, Quest Diagnostics currently has a consensus rating of “Hold” and a consensus price target of $210.69.
Check Out Our Latest Analysis on DGX
Insider Transactions at Quest Diagnostics
In related news, EVP Catherine T. Doherty sold 5,558 shares of Quest Diagnostics stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $206.21, for a total transaction of $1,146,115.18. Following the completion of the sale, the executive vice president directly owned 67,122 shares of the company’s stock, valued at approximately $13,841,227.62. This trade represents a 7.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Patrick Plewman sold 5,662 shares of the business’s stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $204.00, for a total value of $1,155,048.00. Following the completion of the sale, the senior vice president owned 15,381 shares of the company’s stock, valued at $3,137,724. This trade represents a 26.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 24,083 shares of company stock worth $4,945,262 in the last ninety days. 8.16% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Quest Diagnostics
A number of hedge funds have recently bought and sold shares of the business. Quattro Advisors LLC bought a new stake in Quest Diagnostics in the 4th quarter valued at about $25,000. DV Equities LLC bought a new position in shares of Quest Diagnostics during the fourth quarter worth approximately $27,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Quest Diagnostics during the third quarter worth approximately $33,000. State of Wyoming raised its position in shares of Quest Diagnostics by 89.6% in the fourth quarter. State of Wyoming now owns 201 shares of the medical research company’s stock valued at $35,000 after buying an additional 95 shares in the last quarter. Finally, Quarry LP boosted its stake in shares of Quest Diagnostics by 156.0% in the third quarter. Quarry LP now owns 279 shares of the medical research company’s stock valued at $53,000 after buying an additional 170 shares during the period. 88.06% of the stock is owned by institutional investors.
About Quest Diagnostics
Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.
Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.